Please login to the form below

Breast Cancer Now

This page shows the latest Breast Cancer Now news and features for those working in and with pharma, biotech and healthcare.

Lynparza cleared as ovarian cancer maintenance therapy on Cancer Drugs Fund

The Parp-inhibitor drug is now recommended by NICE for use on the Cancer Drugs Fund (CDF) as an option for the maintenance treatment of BRCA mutation-positive, advanced (FIGO stages ... breast cancer, and has new indications in pancreatic cancer and

Latest news

Lynparza set for further expansion with EU approval in breast cancer

There were an estimated 2.1m new cases of breast cancer worldwide last year, and around 30% of women diagnosed with early breast cancer will go on to develop advanced disease. ... The OlympiAD trial supported the approval, and showed Lynparza produced an
NICE nod for Lilly’s breast cancer drug Verzenio via CDF

s Ibrance (palbociclib) – which have previously been approved for first-line use in HR-positive, HER2-negative advanced breast cancer. ... Baroness Delyth Morgan. The decision has been heartily welcomed by charities Breast Cancer Care and Breast Cancer
Tecentriq gains first IO approval in triple negative breast cancer

A coup for Roche in IO field dominated by Keytruda. Roche has stolen a march on market leader Keytruda by gaining the first immuno-oncology approval in triple negative breast cancer. ... Tecentriq (atezolizumab) can now be used in combination with
NICE gives Lilly’s Verzenios chance to compete with rivals

Around 46, 000 women are diagnosed with breast cancer each year in England and Wales, of whom around 8, 000 would be eligible for treatment with a CDK4/6 inhibitor. ... Baroness Delyth Morgan, chief executive at Breast Cancer Now (pictured) welcomed
Daily Brief: Tecentriq set for breast cancer filing, Ocrevus gets NICE thumbs down, NHS needs more cash

Our round-up from pharma, biotech and healthcaare. Tecentriq takes the lead in immunotherapy for breast cancer. ... Checkpoint inhibitor immunotherapy drugs have targeted other tumour types before turning to breast cancer, but now Roche's Tecentriq looks

More from news
Approximately 2 fully matching, plus 33 partially matching documents found.

Latest Intelligence

30 Women Leaders in UK Healthcare (part 3)

28. Baroness Delyth Morgan, Breast Cancer Now Chief Executive. Delyth has been a central figure in breast cancer charities for more than 20 years, building the sector’s voice in health ... In 2015 she oversaw the merger of her organisation Breast
Engaging the digital healthcare professional

Two days after the student midwife’s tweet, UK organisation Breast Cancer Now shared its own response to the guidance, also tweeting to Pfizer and NICE and urging them to work ... Breast Cancer Now is followed by almost 40, 000, and its tweet, which it

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer

Misconception. Reality. Pancreatic cancer is rare [8]. Although the incidence of pancreatic cancer is lower than other common cancers like breast, bowel and lung, pancreatic cancer is the 5. ... Unless substantial improvements are made now, pancreatic

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.